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Insulin delivery and transendothelial insulin transport are two discrete steps that limit 22 muscle insulin action. Angiotensin II type 1 receptor (AT 1 R) blockade recruits microvasculature 23 and increases glucose use in muscle. Increased muscle microvascular perfusion is associated 24 with increased muscle delivery and action of insulin. 25
To examine the effect of acute AT 1 R blockade on muscle insulin uptake and action, rats 26 were studied after an overnight fast to examine the effects of losartan on muscle insulin uptake 27 (protocol 1), microvascular perfusion (protocol 2), and insulin's microvascular and metabolic 28 actions in the state of insulin resistance (protocol 3). Endothelial cell insulin uptake was assessed 29 using 125 I-insulin as tracer. Systemic lipid infusion was used to induce insulin resistance. 30
Losartan significantly increased muscle insulin uptake (~60%, p<0.03), which was associated 31 with 2-3-fold increase in muscle microvascular blood volume (MBV, p=0.002) and flow (MBF, 32 p=0.002). Losartan ± angiotensin II had no effect on insulin internalization in cultured 33 49 50
INTRODUCTION 51
Muscle microvasculature provides endothelial surface area for the exchanges of oxygen, 52 nutrients and hormones between the plasma compartment and muscle interstitium. In the insulin 53 sensitive state, insulin enhances its own delivery to muscle insterstitium by relaxing pre-capillary 54 arterioles to recruit microvasculature thus expanding endothelial exchange surface area, and 55 trans-endothelial transport, two discrete steps that limit insulin's action (1, 2, 12, 45). Insulin's 56 microvascular action is coupled with its metabolic action as inhibition of insulin-mediated 57 microvascular recruitment with nitric oxide (NO) synthase inhibitor decreases insulin-stimulated 58
x MFV) were determined using contrast-enhanced ultrasound (CEU) at time 0 and 30 min, as 119 described previously (8, 10, 21, 22, 40) . 120
121
Protocol 3: Four groups of rats were studied under this protocol (Fig. 1, lower panel) . Each rat 122 received either saline (Group 1, 10 µL/min) or Intralipid + heparin (3.3% and 30 U/ml, Groups 123 2-4) infusion for 3 hrs with a euglycemic hyperinsulinemic clamp (3 mU/kg/min) superimposed 124 in the last 2 hrs (time 0 to 120 min). Groups 3 and 4 received a bolus i.v. injection of losartan 125 (0.3 mg/kg) 5 min before the initiation of insulin clamp. Group 4 rats also received a 126 simultaneous infusion of L-NAME in the last 2 hrs. Arterial blood glucose was determined every 127 10 min using an Accu-Chek Advantage glucometer (Roche Diagnostics, Indianapolis, IN), and 128 30% dextrose (30% wt/vol) was infused at a variable rate to maintain blood glucose within 10% 129 of basal (11, 44). Skeletal muscle MBV, MFV and MBF were determined at time 0, 30, 60, and 130 microvasculature in the postabsorptive state (10). L-NAME at the dose selected (50 µg/kg/min) 142 raises MAP by 20-30 mmHg above baseline without affecting heart rate and completely inhibits 143 insulin-mediated increases in muscle MBV (39). 
Measurement of Plasma NO levels: 160
Plasma NO levels were measured using 280i Nitric Oxide Analyzer (GE Analytical Inc.), 161 according to the manufacturer's instructions. In brief, ice-cold ethanol was added into plasma 162 samples at a ratio of 2:1. The mixture was vortexed, kept at 0 o C for 30 min, and then centrifuged 163 at ~ 14,000 RPM for 5 min. The supernatant was then used for NO analysis.
9
I-insulin as previously reported (4, (17) (18) (19) . 167
In brief, bovine aortic endothelial cells (bAECs) in primary culture were purchased from Lonza 168 (Walkersville, MD). Cells between passages 3 to 6 were cultured in 6-well plates until 80% 169 confluence, serum starved for 18 -22 hrs and then incubated with pre-warmed N-2- To assess whether the increased muscle uptake of insulin was secondary to increased insulin 205 delivery to the microcirculation and/or increased insulin transportation through the vascular 206 endothelium, we first re-confirmed in the current study that losartan injection indeed acutely 207 recruited muscle microvasculature (Fig. 3) . Consistent with our prior report, losartan increased 208 muscle MBV ad MBF by 2-3-fold (p=0.002 for both) within 30 min, without affecting muscle 209 cells, a key step in the process of transendothelial insulin transport. In the presence of excess 211 unlabelled regular insulin, 125 I-insulin internalization decreased by 43% (Fig 4, p=0 .0005). On 212 the contrary, losartan, in the presence or absence of angiotensin II, had no effect on 125 I-insulin 213 internalization (Fig 4) . This suggests that the increased muscle uptake of insulin induced by 214 losartan was secondary to increased insulin delivery via microvascular recruitment and 215 endothelial uptake of insulin is not the rate-limiting step in this process. 216 217
Losartan prevents lipid-induced metabolic insulin resistance via NO-dependent mechanism: 218
We next examined whether the increase in muscle microvascular recruitment and insulin uptake 219 help prevent lipid-induced metabolic insulin resistance. Systemic lipid infusion potently 220 inhibited insulin-stimulated whole body glucose disposal (by ~ 40%, p<0.0001) but this 221 inhibitory effect was completely reversed with one dose of losartan injection before the initiation 222 of insulin clamp ( increased muscle delivery of insulin as evidence has strongly suggested that it is the insulin 269 concentrations in the muscle interstitium, not plasma, that correlate with insulin's metabolic 270 effects (7). 271
We and others have previously reported that insulin potently increases muscle MBV thus 272 expands microvascular endothelial surface area (13, 15, 16, 29, 31, 35 ). In the current study, 273 insulin again significantly increased muscle MBV and MBF, and these effects were abolished in 274 the presence of systemic lipid infusion, which is consistent with prior reports in both laboratory 275 animals (13, 21) and humans (28, 31). Administration of losartan prior to the initiation of insulin 276 infusion in the presence of lipid infusion increased muscle MBV by ~ 2-3-fold ( MBV and muscle use of glucose, AT 2 R antagonism with PD123319 renders an ~ 80% reduction 292 in muscle MBV and a reduced muscle use of glucose (10). In the hyperinsulinemic state, 293 unopposed stimulation of AT 1 R by administration of AT 2 R antagonist PD123319 markedly 294 decruits microvasculature, reduces muscle insulin uptake and attenuates insulin's metabolic 295 action (9). Our current results demonstrate that AT 1 R activity plays important role in the 296 regulation of insulin's microvascular and metabolic responses in muscle in the insulin resistant 297 state and strongly suggest that pharmacological manipulation of microvascular AT 1 R and AT 2 R 298 activity ratio could be an important therapeutic target for the prevention and management of 299 obesity and diabetes. 300
Despite lipid infusion induced a significant decrease in insulin-mediated glucose 301 disposal, insulin-stimulated Akt phosphorylation was similar among all groups. This is not 302 surprising as previous evidence has suggested that Akt is probably not the critical node in insulin 303 resistance. Indeed, insulin activation of Akt isoforms is normal in muscle of obese nondiabetic 304 and obese diabetic subjects, despite decreases of ~ 50% and 40% in IRS-1-and IRS-2-associated 305 PI3-kinase activity, and ~ 60% decrease in insulin-stimulated glucose disposal in obese diabetic 306 subjects (25). While lipid infusion for a longer period of time than the current study (5.5 vs. 3 307 hrs) did reduce insulin-mediated Akt1 phosphorylation by 55%, insulin-stimulated Akt2 308 phosphorylation paradoxically increased by ~40% and Akt3 phosphorylation did not change in 309 rat muscle (26). 310
In conclusion, acute AT 1 R blockade with losartan increases muscle insulin uptake mainly 
